Access GI Expertise, Educational Resources and Support for You and Your Patients

A Free ACG Member Benefit Designed to Help You and Your Patients!
Learn More and Join Today at GIONDEMAND.COM

2022
ACG'S ENDOSCOPY SCHOOL & SOUTHERN REGIONAL POSTGRADUATE COURSE
DECEMBER 2-4, 2022 | GRAND HYATT NASHVILLE, TENNESSEE

Register online: meetings.gi.org
All attendees will be muted and will remain in Listen Only Mode.

Type your questions here so that the moderator can see them. Not all questions will be answered but we will get to as many as possible.
**How to Receive CME and MOC Points**

**LIVE VIRTUAL GRAND ROUNDS WEBINAR**

ACG will send a link to a CME & MOC evaluation to all attendees on the live webinar.

ABIM Board Certified physicians need to complete their MOC activities by **December 31, 2022** in order for the MOC points to count toward any MOC requirements that are due by the end of the year. No MOC credit may be awarded after **March 1, 2023** for this activity.

**MOC QUESTION**

If you plan to claim MOC Points for this activity, you will be asked to: Please list specific changes you will make in your practice as a result of the information you received from this activity.

Include specific strategies or changes that you plan to implement. THESE ANSWERS WILL BE REVIEWED.
ACG Virtual Grand Rounds

Join us for upcoming Virtual Grand Rounds!

Week 45 – Thursday, November 10, 2022
GI Diseases and Endoscopy in Pregnancy and Postpartum Period: The ACG Pregnancy Monograph
Faculty: Sunanda V. Kane, MD, MSPH, FACG; Vivek Kaul, MD, FACG; and Shivangi T. Kothari, MD, FACG
At Noon Eastern and NEW! 8pm Eastern!

Week 46 – Thursday, November 17, 2022
COVID-19 Vaccine Update
Faculty: Freddy Caldera, DO
Moderator: Daniel J. Pambianco, MD, FACG
At Noon Eastern and NEW! 8pm Eastern!

There will be no ACG Virtual Grand Rounds November 24th

Visit gi.org/ACGVGR to Register

ACG's Endoscopy School & Southern Regional Postgraduate Course
December 2-4, 2022 | Grand Hyatt Nashville, Tennessee
Register online: meetings.gi.org
Disclosures

Kathy P. Bull-Henry, MD, MBA, FACG
Dr. Bull-Henry has no relevant financial relationships with ineligible companies.

John R. Saltzman, MD, FACG
Dr. Saltzman has no relevant financial relationships with ineligible companies.

All treatments described are Off Label

*All of the relevant financial relationships listed for these individuals have been mitigated

Obscure Bleeding:
Are There Options After Endoscopy?

Kathy Bull-Henry, MD, FACG
Medical Director, JHBMCEndoscopy Unit
Johns Hopkins Bayview Medical Center
Baltimore, Maryland
Learning Objective

• Evaluate testing and management strategies when endoscopy doesn’t reveal the source of bleeding

Obscure GI Bleeding

• Unidentified origin after upper and lower GI evaluation
• Most bleeding sources are in the small bowel
Table 2

<table>
<thead>
<tr>
<th>Common causes</th>
<th>Rare causes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Under age 40 years</strong></td>
<td><strong>Hemoch–Schoenlein purpura</strong></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Small bowel varices and/or portal hypertension enteropathy</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>Ameglosis</td>
</tr>
<tr>
<td>Diverticulitis</td>
<td>Blue rubber bleb nevus syndrome</td>
</tr>
<tr>
<td>Neoplasia</td>
<td>Pseudoxanthoma elasticum</td>
</tr>
<tr>
<td>Polyposis syndromes</td>
<td>Osler–Weber–Rendu syndrome</td>
</tr>
<tr>
<td>Peutz–Jeghers syndrome</td>
<td>Kaposis sarcoma with AIDS</td>
</tr>
<tr>
<td><strong>Over age 40 years</strong></td>
<td></td>
</tr>
<tr>
<td>Fistulae</td>
<td>Plummer–Vinson syndrome</td>
</tr>
<tr>
<td>Polyposis syndromes</td>
<td>Ehlers–Danlos syndrome</td>
</tr>
<tr>
<td>Hereditary polyposis syndromes (FAP, Peutz–Jeghers)</td>
<td>Inherited polyposis syndromes (FAP, Peutz–Jeghers)</td>
</tr>
<tr>
<td>Malignant atrophic papulosis</td>
<td>Malignant atrophic papulosis</td>
</tr>
<tr>
<td>Hereditary</td>
<td>Hereditary</td>
</tr>
<tr>
<td>Aorto-enteric fistula</td>
<td>Hereditary</td>
</tr>
<tr>
<td>Hemorrhoidal</td>
<td>Aorto-enteric fistula</td>
</tr>
<tr>
<td>FAP, familial adenomatous polyposis</td>
<td>Neurofibromatosis</td>
</tr>
<tr>
<td>NSAID, nonsteroidal anti-inflammatory drug.</td>
<td>Neurofibromatosis</td>
</tr>
</tbody>
</table>

Causes of small bowel bleeding.
Outcomes after Endoscopic Therapy

- Rebleeding rates from vascular lesions ranges from 20-46%
- Risk factors for recurrent bleeding
  - Number of vascular lesions
  - Age over 65 years
  - Presence of lesions in the jejunum
  - Presence of aortic stenosis (Heyde’s syndrome)
  - Left ventricular assist devices
  - Chronic renal failure
  - Usage of anticoagulant medications
  - Need for transfusion

Nonendoscopic Therapy

Supportive

**Oral Iron Supplementation**
- Ferrous sulfate, ferrous gluconate, ferrous fumarate, ferric maltol, and iron polysaccharide.
- Most contain 60 to 70 mg of elemental iron, of which only 25% is absorbed.
- The most effective oral iron regimen dosing is every 48 h
- Side effects include nausea, dyspepsia, constipation, diarrhea, dark or melenic stools, and pill esophagitis

**IV Iron Supplementation**
- Iron sucrose, ferric carboxymaltose, ferric gluconate, low molecular weight iron dextran, iron isomaltoside, and ferumoxytol
- Iron sucrose and ferric carboxymaltose most commonly used
  - Ferric carboxymaltose can be given in 750 mg doses for a full treatment course in 1–2 doses
  - Iron sucrose is given in 200 mg doses, requiring 5 doses for a full course

References:
- Samaha E. Am J Gast 2012;107:246-6
- Shinouaki S. Clin Gastro Hepatol 2010;8:151-8
- Arakawa D et al. GIE 2009;69:866-74
- Westrich D. Curr Gastroenterol Rep 2021;23:12
Nonendoscopic Treatment Options

- Hemostatic Treatment
  - Stop bleeding
- Prophylactic Treatment
  - Prevent rebleeding
- Rescue Treatment
  - When other modalities have failed

Hemostatic Therapy

- Selective embolization by angiography
  - Used in actively bleeding lesions
  - Hemostatic effectiveness 80-90%
  - Selectively catharize vessel feeding the avm
  - Inject embolizing agent- biodegradable sponge, microcoils
  - Complex procedure
  - Complication rate 5-9%
    - 2% are severe
    - Hematoma, hematomas, bowel infarction, arterial dissection, thrombosis, and pseudoaneurysms
Prophylactic Therapy
Pharmacologic Therapy

• Hormonal therapy
  • Estrogen +/- progesterone
• Somatostatin analogs
  • Octreotide
• Antiangiogenics
  • Thalidomide
  • Lenalidomide
  • Bevacizumab

Management of Gastrointestinal Angiodysplastic Lesions (GIADs): A Systematic Review and Meta-Analysis

• Twenty-two studies, 831 patients with ADs:
  • 14 papers reporting the efficacy of endoscopic therapy for ADs in 623 patients,
  • 2 case – control studies involving hormonal therapy for 63 subjects,
  • 4 studies reporting outcomes with somatostatin analogs in 72 patients,
  • 2 papers reporting outcomes with AVR in 73 patients.
• No studies involving diagnostic or provocative angiography met the inclusion criteria

Am J Gastro 2014;109:474
Prophylactic Therapy

Hormonal Therapy

• Hormonal therapy- Estrogen +/- progesterone
• Unknown mechanism, increases the number of circulating activated platelets thereby shortening the bleeding time
  • Based on two case – control studies with 63 pts
  • (2001): Re-bleeding occurred in 13/33 of the treated group and 16/35 in the placebo arm (P = 0.6).
  • (1992): Rebleeding occurred in 15/30 in treated group vs 15/34 in controls

• Hormonal therapy was not effective for bleeding cessation

Am J Gastro 2014;109:474
Gastro 2003;113:1073

Prophylactic Therapy

Somatostatin Analogs- Octreotide

• Somatostatin analogs- Octreotide
  • Mechanisms:
    • Inhibition angiogenesis by inhibiting vascular epithelial growth factor
    • Decreased duodenal and splanchnic blood flow
    • Increased vascular resistance
    • Enhanced platelet aggregation
    • Reduced portal and mesenteric blood flow via inhibition of vasodilator peptides
  • (2007) 32 pts Octreotide 50 mcg 12h SQ and 38 pts placebo
    • Rebleeding lower in octreotide pts 23% vs 48% in placebo pts.
    • 1-yr and 2-yr rebleeding free rates were higher in the octreotide pts 77% and 68% vs placebo group 55% and 36%
  • 4 studies, 72 pts
    • The pooled odds ratio was 14.5 (95 % CI: 5.9 – 36) for bleeding cessation

• Octreotide was effective for bleeding reduction

Am J Gastro 2014;109:474
Am J Gastro 2007;102:254
Gastrointest Endoscopy Clin N Am 2017;27:51
Prophylactic Therapy

Antiangiogenics

• Thalidomide
  • Thalidomide inhibits vascular endothelial growth factor (VEGF) to decrease angiogenesis
  • (2011) randomized pts to 100 mg of thalidomide vs. iron therapy for 4 months, demonstrated decreased re-bleeding rates and transfusions
    • Thalidomide reduced transfusion dependent patients (11% vs 48%); Reduced re-hospitalizations due to bleeding (39% vs 100%)
    • 71% of the thalidomide group reported side effects-fatigue and somnolence
  • (2012) treated 12 refractory GIAD patients and demonstrated an increase in hemoglobin values (6.5 g/dl to 12.1 g/dl) after 4 months in 9/12 patients
  • Thalidomide effective for bleeding reduction but has significant side effects

Gastro 2011;41:1629
Rev Esp Enferm Dig 2012;104:69

• Lenalidomide
  • Thalidomide analog
  • Developed in the 1990s to achieve improved potency in the absence of significant side effects.
  • Inhibits vascular endothelial growth factor (VEGF) to decrease angiogenesis
  • Retrospective case series, 5 pts with VWD and bleeding AD, Decrease blood transfusion
  • Needs more studies

• Bevacizumab
  • Avastin- Monoclonal antibody against vascular endothelial growth factor
  • Strong antiangiogenic activity and a favorable side-effect profile

Haemophilia 2018;24:278
World J Gastro 2007;13:5979
Rescue Therapy

- Radiological, endoscopic and pharmacological treatments

- Surgery
  - Last resort; Discrete lesions
  - Intraoperative enteroscopy guided resection
    - 47 consecutive patients with IOE via an enterotomy: A bleeding source was identified on IOE in 73% of all cases.
  - Angiography guided resection
    - Case report: Methylene blue injection via a super-selective angiographic microcatheter followed by focused enterectomy

Aortic Stenosis and Heyde’s Syndrome

- Relationship between severe aortic stenosis and angiodysplasia
- Destruction of von Willebrand factor when passing through a stenosed aortic valve (acquired von Willebrand syndrome)
- Chronic hypoxia from aortic stenosis
  - Leads to sympathetic induced vasodilation and smooth muscle relaxation, which in turn leads to formation of angioectasias and subsequent bleeding
- Review 2021: 46 Case reports, 55 pts with AS,
  - 43 underwent AVR, and 12 received transcatheter AVR.
  - Two patients had recurrent gastrointestinal bleeding.
- AVR may be effective treatment for Heyde’s
LVAD Patients

- Octreotide
  - Dosing: 50 to 100 μg subcutaneous (SQ) twice daily (BID) or octreotide long-acting release (LAR) 20 to 30 mg intramuscularly (IM) monthly.
  - 26 LVAD Pts, Octreotide reduced bleeding episodes (Juricek, 2018)
    - LAR pre-treatment episodes was 3 ± 2.4 per year vs 0.7 ± 1.3 per year post treatment.
    - 43% of the cohort was free of further bleeding episodes in follow-up
    - Side effects include diarrhea, abdominal pain, nausea, vomiting, gallstone formation, glucose abnormalities, pruritis, hypothyroidism, headaches and dizziness
  - First line therapy

- Thalidomide
  - Dosing: 50 mg of thalidomide was used daily or twice daily with titration to 100 mg twice daily with bleeding episodes
  - 17 LVAD pts, Single center, Retrospective review, Thalidomide reduced GI bleeding episodes (Namdaran, 2019)
    - Pretreatment was 4.6 episodes per year vs 0.4 episodes per year.
    - Reduced blood transfusions from 36.1 to 0.9 units per year.
    - High adverse event rate; ranging from 58-71%. The more common adverse events encountered were dizziness, neuropathy, fatigue, constipation, transaminitis, and somnolence
  - Well tolerated without side effects in the study participants

- Bevacizumab
  - Humanized monoclonal antibody against VEGF, in lowering the rate of GI bleeding in refractory cases
  - 5 LVAD pts, reduced blood transfusions and hospitalizations
  - Annual decreases in blood product usage from 45.8 to 6.0 units, reduced hospitalizations per year from 5.6 to 1.7 and an annual reduction in endoscopy from 10.6 to 2.1 procedures.
  - Well tolerated without side effects in the study participants

- Danazol
  - Androgen-like steroid
  - Decreases GIB by inhibiting endothelial permeability
  - Danazol has demonstrated effectiveness in patients with LVAD and refractory GIB requiring multiple procedures
    - Decreased hospitalizations and reduced blood transfusions

- ACEI/ARB
  - May reduce GI bleeding
  - 131 LVAD pts, 31 patients that did not receive an ACEI/ARB, 48% had a GI bleeding vs 24% of those that received an ACEI/ARB
  - Mechanism mainly centers around the downregulation of TGF-β
  - Needs further studies
Take Home Points

• Endoscopic therapy
  • Treatment of gastrointestinal bleeding in patients with angiodysplasias is clinically challenging
  • Initial endoscopic therapy is effective, but the pooled recurrence bleeding rate was 36% over 22 months.
  • Re-bleeding increased to 45% when studies included only small-bowel Ads

• Iron supplementation

• Medical Therapy
  • Hormonal therapy is not effective
  • Octreotide therapy is effective
  • Antiangiogenic therapy shows promise
  • Evaluate for prothrombotic conditions before considering treatment with pharmacologic therapy
  • The risk for thromboembolic events and potential benefits of decreased GI bleeding should be carefully weighed before using these drugs

Take Home Points

• LVAD patients
  • Thalidomide, Danazol, Octreotide reduce recurrent GI bleeding
  • Bevacizumab promising

• Aortic Stenosis (Heyde’s Syndrome)
  • Aortic Valve Replacement may reduce recurrent GI bleeding
Thank you

Questions?

Kathy P. Bull-Henry, MD, MBA, FACG

John R. Saltzman, MD, FACG
CONNECT AND COLLABORATE IN GI

ACG & CCF IBD Circle
ACG Hepatology Circle
ACG GI Circle
Connect and collaborate within GI
ACG Functional GI Health and Nutrition Circle
ACG Women in GI Circle

ACG’s Online Professional Networking Communities
LOGIN OR SIGN-UP NOW AT: acg-gi-circle.within3.com